Logo

CRBP

Corbus Pharmaceuticals Holdings, Inc.

CRBP

Corbus Pharmaceuticals Holdings, Inc. • NASDAQ
$11.54 ▼ -2.86% (-0.34)
Market Cap $144.66 M
52w High $20.56
52w Low $4.64
Dividend Yield 0%
P/E -2.1
Volume 158.52K
Outstanding Shares 12.54M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $24.417M ▲ $-23.342M ▼ 0% $-1.9 ▼ $-23.342M ▼
Q2-2025 $0 $19.052M ▲ $-17.662M ▼ 0% $-1.44 ▼ $-17.562M ▲
Q1-2025 $0 $4.133M ▼ $-16.978M ▼ 0% $-1.39 ▼ $-18.578M ▼
Q4-2024 $0 $12.459M ▼ $-9.53M ▲ 0% $-0.78 ▲ $-9.384M ▲
Q3-2024 $0 $15.505M $-13.783M 0% $-1.15 $-13.25M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $26.983M ▼ $109.514M ▼ $17.367M ▲ $92.147M ▼
Q2-2025 $116.592M ▼ $125.085M ▼ $14.094M ▲ $110.991M ▼
Q1-2025 $132.787M ▼ $139.931M ▼ $12.825M ▼ $127.106M ▼
Q4-2024 $149.062M ▼ $155.879M ▼ $13.451M ▼ $142.428M ▼
Q3-2024 $159.362M $164.171M $13.673M $150.498M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-23.342M ▼ $-15.55M ▲ $19.638M ▲ $2.851M ▲ $6.939M ▲ $-15.55M ▲
Q2-2025 $-17.662M ▼ $-16.599M ▼ $17.743M ▼ $0 $1.144M ▼ $-16.599M ▼
Q1-2025 $-16.978M ▼ $-16.421M ▼ $18.123M ▲ $0 ▲ $1.702M ▲ $-16.421M ▼
Q4-2024 $-9.53M ▲ $-10.942M ▲ $8.73M ▲ $-13K ▼ $-2.225M ▲ $-10.942M ▲
Q3-2024 $-13.783M $-13.942M $-15.365M $25.044M $-4.263M $-13.942M

Five-Year Company Overview

Income Statement

Income Statement Corbus is still a pure R&D story with essentially no product revenue yet, which is typical for an early-stage biotech. The income statement is driven almost entirely by research, clinical, and corporate spending. Losses have been steady over the past few years, and while they appear to be gradually narrowing, the company remains firmly unprofitable. The very large swings in per-share figures mostly reflect stock structure changes, not a dramatic change in the underlying business. Overall, the income statement shows a company investing ahead of any commercial payoff, with future results heavily dependent on clinical and regulatory outcomes.

Balance Sheet

Balance Sheet The balance sheet is small and lean, reflecting an early-stage biotech without significant physical assets. Cash and total assets are modest, but debt has been reduced to minimal levels, which lowers financial pressure. Equity turned from slightly negative to positive recently, suggesting fresh capital and some repair of the balance sheet. Still, the company’s resources are limited, so its ability to fund trials will likely depend on continued access to capital markets or partnerships. There is little asset cushion if timelines slip or trials become more expensive than expected.

Cash Flow

Cash Flow Cash flows are consistently negative, driven by operating costs for R&D and corporate overhead. There is effectively no spending on fixed assets, so almost all cash outflow reflects the cost of running trials and building the pipeline. The pattern shows a classic cash-burning biotech: predictable outflows with no offsetting inflows from product sales. This means the runway and future dilution or partnering needs are central issues; the business model relies on funding external to operations until a drug is approved or out-licensed.

Competitive Edge

Competitive Edge Corbus competes in very crowded, high-stakes areas—oncology and obesity—yet it is trying to differentiate with focused, science-driven niches. Its lead oncology asset targets a known cancer marker with a more finely engineered drug design that aims to improve safety versus an existing approved therapy. Another oncology program takes a novel angle on a well-known immune-suppressive pathway in tumors, placing it in a less crowded slice of the immunotherapy landscape. In obesity, Corbus is not trying to displace current market leaders directly but to offer an oral, mechanistically distinct option that could complement or extend existing treatments. Overall, the company is small relative to its competitors, but it is aiming for differentiation through design, safety, and combination potential rather than sheer scale.

Innovation and R&D

Innovation and R&D Innovation is clearly the core of Corbus’s strategy. The pipeline spans three distinct platforms: a next-generation antibody-drug conjugate for Nectin-4–expressing cancers, a novel integrin-targeting antibody to modulate TGF-beta in the tumor environment, and a peripherally restricted CB1 inverse agonist aimed at obesity without the brain-related side effects that hurt earlier drugs in this class. Each program is built around a specific scientific insight—more precise targeting, improved safety profiles, or better combination potential with standard-of-care treatments. The company has been actively building intellectual property and securing regional rights, and it has obtained a favorable regulatory designation for its lead ADC in certain cancers. However, all programs are still early or mid-clinical stage, so the scientific promise has yet to be validated in large patient studies, and R&D risk remains high.

Summary

Corbus is an early-stage biotech that has reshaped itself around three differentiated programs in oncology and obesity. Financially, it looks like a typical clinical-stage company: no commercial revenue, ongoing losses, modest assets, and a dependable but finite cash burn that will require future funding or partnerships. Strategically, its strength lies in focused innovation—attempting to improve safety, broaden use, or enhance combination potential in areas where unmet needs are still substantial. The main opportunities come from successful trial readouts, regulatory support, and potential collaboration deals. The main risks are the usual binary biotech uncertainties: clinical setbacks, safety issues, or funding challenges before any product reaches the market. Corbus’s future will be largely determined by how its current trials read out over the next few years and whether the differentiated science translates into real-world clinical and commercial value.

NEWS

November 6, 2025 · 8:00 AM UTC

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Read more

October 31, 2025 · 2:40 AM UTC

Corbus Pharmaceuticals Announces Pricing of Public Offering

Read more

October 30, 2025 · 4:31 PM UTC

Corbus Pharmaceuticals Announces Proposed Public Offering

Read more

October 18, 2025 · 3:00 AM UTC

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Read more

September 16, 2025 · 8:00 AM UTC

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Read more